Company | Ticker | Business Description | Underwriters | Offer Date |
---|---|---|---|---|
Aura Biosciences> | AURA> | Phase 2 biotech developing virus-like drug conjugates for ocular and urologic solid tumors. | TD Cowen Leerink Partners |
10/28/21 |
CalciMedica> | CALC> | Phase 2 biotech developing long-acting formulations of drugs for ocular diseases. | Leerink Partners Piper Sandler |
09/24/20 |
EOM Pharmaceutical> | EOM> | Developing in-licensed therapies for inflammatory and ocular diseases. | EF Hutton |
Withdrawn |
Gyroscope Therapeutics> | VISN> | UK-based Phase 2 biotech developing gene therapies for ocular diseases. | Morgan Stanley Goldman |
Withdrawn |
Oculis> | OCS> | Blank check company formed by LSP targeting the life sciences industry in Europe (completed 3/3/2023). | Credit Suisse Kempen |
03/15/21 |
Zhaoke Ophthalmology> | |
News Results for OCUL |
---|